SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as investors anticipate earnings and key updates on its AI/HPC pivot, with discussions focusing on potential deals and infrastructure expansion. Community chatter highlights both bullish expectations for a short squeeze and skepticism around earnings performance, particularly compared to sector peers. Upgrades in price targets are contributing to the overall interest in the stock.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) Public Ltd Co - Ordinary Shares - Class A

SMX is trending due to recent partnerships and expansion updates, particularly around its traceability narrative, with the community actively discussing its potential. Despite positive news, the stock's volatile price action and history of reverse splits are generating mixed sentiment. Traders are also monitoring high short borrow fees and the potential for a squeeze.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending due to a mix of factors including unusual options activity, discussion of AI integration, and overall sentiment regarding the company's leadership and strategic direction. Community members are actively debating the impact of AI on CRM's growth, comparing it to competitors like Palantir, and scrutinizing the CEO's actions and statements. Some express concerns about the company's performance relative to the broader market and its peers in the software sector.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

ZS is trending following earnings, with community discussion focused on the stock's price action despite positive results and raised guidance. Some traders are expressing frustration over the lack of upward movement and debating potential entry points, while others are comparing ZS to competitors like PLTR and assessing its valuation.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARA is trending amid Bitcoin's volatility, with community members debating its correlation to BTC's price movements and expressing frustration over its performance compared to other miners. Discussions also focus on management's performance, insider selling, and potential AI pivots, while some anticipate a significant short squeeze.

Symbotic, Inc. is an automation technology company, which engages in a robotics and automation-based product movement technology platform. It focuses on developing, commercializing, and deploying innovative, end-to-end technology solutions for supply chain operations. It operates through the United States and Canada geographical segments. The company was founded by Richard B. Cohen on December 11, 2020 and is headquartered in Wilmington, MA.

Symbotic Inc - Ordinary Shares - Class A

Symbotic Inc 

SYM is trending due to strong bullish sentiment and discussions around potential short squeezes, fueled by its advancements in AI-powered warehouse automation and a substantial order backlog. Community members are debating whether the stock is overvalued after its recent surge, while others point to its key partnerships and potential for further growth in the robotics sector. The stock's price movements and potential resistance levels are also being closely watched by traders.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending as investors assess its role in the AI landscape, particularly regarding its partnership with Google and its TPU technology. Community members are discussing the potential for the stock to reach $400 soon, while also weighing factors like RSI levels and upcoming earnings. Talk of rotation into AVGO from other chipmakers is circulating among investors.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is trending as investors discuss its potential, citing its AI capabilities, military contracts, and partnership with NVDA. The community highlights its undervaluation and anticipates significant growth, with some speculating about a potential contract announcement or buyout. Discussions also mention the possibility of expanding into software via acquisitions to improve profit margins.

Kohl's Corp. engages in the operation of family-oriented department stores. Its business line includes apparel, footwear, and accessories for women, men, and children, home products, beauty products, and accessories. The stores generally carry a consistent merchandise assortment with some differences attributable to regional preferences. The company was founded in 1962 and is headquartered in Menomonee Falls, WI.

Kohl`s Corp.

Kohl's Corp

Kohl's ($KSS) is trending amidst community discussions around its potential for a short squeeze and overall value play, especially with some drawing comparisons to meme stocks. The stock's movement is also linked to broader retail sector trends and reactions to potential tariff impacts. Some see the company as undervalued with real estate assets, while others remain bearish due to past performance and management changes.

Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. It operates through the Biopharmaceutical and Strategic Investments segments. The Biopharmaceutical segment focuses on furthering the research and development of the drug candidates and the development of a treatment for alcohol misuse for application in hospitals and other medical practices. The Strategic Investments segment is involved in the generation of returns and cash flow through the issuance of loans secured by residential property, with FSD Strategic Investments having a first or second collateral mortgage on the secured property. The company was founded by Thomas Fairfull, Zeeshan Saeed, and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Quantum BioPharma Ltd. - Ordinary Shares - Class B (Sub Voting)

Quantum BioPharma Ltd

Quantum BioPharma is trending due to its ongoing $700M lawsuit alleging stock manipulation, amplified by recent media coverage and community optimism around potential short squeezes. Discussions also focus on the company's fundamentals, particularly updates on its MS drug development and potential for revenue growth. Community members are actively debating the stock's volatility and potential upside amid these developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Traders Purchase Large Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock traders acquired 4,601 call options on the stock. This...

Esperion Therapeutics (NASDAQ:ESPR) Coverage Initiated at Piper Sandler

Piper Sandler assumed coverage on Esperion Therapeutics in a report on Tuesday. They set an "overweight" rating and a $9.00 target price on the stock...

<ul class="summary-bullets"><li>Piper Sandler projected long-term growth backed by rising use of Esperion’s LDL-lowering therapies and expanding payer coverage.</li><li>Q3 revenue rose sharply as U.S. product sales and collaboration income continued to strengthen.</li><li>The recent Japan launch and milestones from partner Otsuka added to investor optimism about Esperion’s global expansion.</li></ul>Esperion Therapeutics shares climbed to their highest levels in nearly a year on Tuesday after a bullish initiation from Piper Sandler and fresh progress on the company’s international launch plans helped lift investor sentiment.The stock closed 16.4% higher at $3.69 on Tuesday and edged up another 0.3% in after-hours trading, also logging its best session in almost four months.&nbsp;<h2 class="st-heading-2">Piper Sandler Calls Esperion A Strong Risk-Reward Play</h2>Piper Sandler initiated coverage with an ‘Overweight’ rating and projected a potential 144% upside, describing Esperion as a strong risk-reward play supported by accelerating demand for its cholesterol-lowering drug franchise. The firm highlighted the strength of the company’s bempedoic acid–based therapies, Nexletol and Nexlizet, and said it expects continued rapid volume and sales expansion as physicians shift toward non-statin low-density lipoprotein (LDL)-lowering options, according to a report by&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://in.investing.com/news/analyst-ratings/piper-sandler-initiates-esperion-therapeutics-stock-with-overweight-rating-93CH-5124964">Investing</a>.The brokerage pointed to several drivers of long-term growth, including a wide label that covers primary prevention, evolving clinical guidelines that increasingly support the drug class, and broad payer access. A cardiologist-focused survey conducted by the firm reinforced confidence in the therapies’ adoption trajectory.Piper Sandler said it expects Esperion’s products to reach over $650 million in peak U.S. sales, with additional contributions from ex-U.S. royalties, and noted that recent agreements with generic filers provide visibility into exclusivity extending to 2040.Piper Sandler added that Esperion’s risk-reward profile is attractive, noting the stock trades at an enterprise value of roughly 10x estimated 2026 EBITDA, with high visibility into a long-term EBITDA compound annual growth rate above 30% from 2026 through 2031. This long-term view remains intact even as the company reported an EBITDA loss of $29.27 million over the last twelve months.<h2 class="st-heading-2">Esperion Posts Strong Q3 Growth</h2>Esperion reported third-quarter (Q3) total revenue of $87.3 million, an increase of 69% year-on-year, with U.S. net product revenue rising 31% year-on-year to $40.7 million. Collaboration revenue strengthened as well, supported by higher royalty sales and product supply to partners. The company reported an EBITDA loss of $29.27 million, net loss of $31.3 million, and ended the quarter with $92.4 million in cash and cash equivalents. U.S. commercial coverage expanded to more than 90% of commercial lives and over 80% of Medicare beneficiaries, and total prescription volume increased during the period.<h2 class="st-heading-2">Japan Launch Builds Global Momentum</h2>Esperion’s upward momentum comes shortly after a major international milestone. Last week, the company said that its partner Otsuka Pharmaceutical received National Health Insurance Price Listing in Japan and launched Nexletol for hypercholesterolemia and familial hypercholesterolemia. Japan represents the third largest global market for cardiovascular prevention, marking a significant expansion opportunity for Esperion’s cholesterol franchise.Under the agreement, Esperion will receive a $90 million payment tied to Otsuka’s recent regulatory and pricing achievements. The company is also eligible for additional sales milestone payments and tiered royalties of 15% to 30% on net sales in Japan.<h2 class="st-heading-2">Stocktwits Traders Signal Long-Term Confidence</h2>On Stocktwits, retail sentiment for Esperion was ‘extremely bullish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:972/146;" src="https://news.stocktwits-cdn.com/espr_stock_png_0574a99904.webp" alt="espr stock.png" width="972" height="146"><figcaption>ESPR sentiment and message volume as of November 25 | Source: Stocktwits</figcaption></figure>One user said they did not see a buyout happening soon, noting that Esperion already has a growing commercial drug, additional pipeline assets and a path toward profitability.<stembedurl>https://stocktwits.com/Petey3163/message/637466961</stembedurl>Another user said they expected to remain invested for 18 to 24 months, describing cardiovascular opportunities as early and ESP-2001 as still upcoming, and added that they had built a large position and planned to hold.<stembedurl>https://stocktwits.com/Lskynrd1/message/637466633</stembedurl><a href="https://stocktwits.com/symbol/ESPR">Esperion Therapeutics’ stock</a> has risen 67% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Esperion Therapeutics Inc. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug 

Piper Sandler projected long-term growth backed by rising use of Esperion’s LDL-lowering therapies and expanding payer coverage.

Equity

Esperion Therapeutics (NASDAQ:ESPR) Trading Up 4.1% - Should You Buy?

Esperion Therapeutics (NASDAQ:ESPR) Shares Up 4.1% - Still a Buy...

Esperion Partner HLS Receives Health Canada Approval For NILEMDO To Lower LDL-Cholesterol

(RTTNews) - Esperion Therapeutics, Inc. (ESPR) on Tuesday said HLS Therapeutics Inc. (HLS), its partner in Canada for NILEMDO, has received Health Canada approval to market NILEMDO for reducing...

HC Wainwright Has Positive Outlook for ESPR FY2025 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - HC Wainwright increased their FY2025 earnings estimates for shares of Esperion Therapeutics in a note issued to investors on Thursday...

Research Analysts Set Expectations for ESPR FY2026 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued to...

Esperion Therapeutics (NASDAQ:ESPR) Trading Down 13.1% After Earnings Miss

Esperion Therapeutics (NASDAQ:ESPR) Trading Down 13.1% After Earnings Miss...

ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down

Esperion's Q3 loss widens despite a 69% jump in revenues.  Mixed results and investor jitters probably drag ESPR shares down 15%.

Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -77.78% and +4.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Esperion Therapeutics Inc.

$NVDA

$AAPL

$GOOG/$GOOGL

$MSFT

Which company ends 2025 with the largest market cap?

Current Price	$3.99
Prev Close	$3.69
Open	$3.70
Dividend Yield	0.00%
50-Day Moving Average	$2.81
Beta	1.05
Avg. Volume	7.54M
PE Ratio	-6.89

52-Week High	$3.94
52-Week Low	$0.6925
Market Capitalization	$889.5M
EPS (Annual)	-$0.2764
Price to Book	-1.68
Revenue Per Employee	$1.09M
Enterprise Value/EBITDA	N/A

ESPR
Esperion Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ESPR News

ESPREsperion Therapeutics Inc.